Bank of Montreal Can Buys New Stake in Trinity Biotech PLC (TRIB)
Bank of Montreal Can bought a new position in Trinity Biotech PLC (NASDAQ:TRIB) during the second quarter, according to its most recent filing with the SEC. The firm bought 726,778 shares of the company’s stock, valued at approximately $8,242,000.
A number of other hedge funds have also added to or reduced their stakes in the company. Royce & Associates LP boosted its position in shares of Trinity Biotech PLC by 13.7% in the first quarter. Royce & Associates LP now owns 799,098 shares of the company’s stock worth $9,317,000 after buying an additional 96,500 shares in the last quarter. Adirondack Research & Management Inc. boosted its position in shares of Trinity Biotech PLC by 1.3% in the first quarter. Adirondack Research & Management Inc. now owns 415,353 shares of the company’s stock worth $4,843,000 after buying an additional 5,466 shares in the last quarter. Finally, Kimelman & Baird LLC boosted its position in shares of Trinity Biotech PLC by 0.6% in the first quarter. Kimelman & Baird LLC now owns 109,367 shares of the company’s stock worth $1,275,000 after buying an additional 675 shares in the last quarter. 71.14% of the stock is owned by hedge funds and other institutional investors.
Trinity Biotech PLC (NASDAQ:TRIB) traded up 0.31% during midday trading on Friday, reaching $6.57. 398,351 shares of the company traded hands. The company has a 50 day moving average of $12.21 and a 200-day moving average of $11.68. Trinity Biotech PLC has a 12-month low of $5.76 and a 12-month high of $13.68. The stock has a market capitalization of $151.22 million, a P/E ratio of 27.96 and a beta of 0.97.
Trinity Biotech PLC (NASDAQ:TRIB) last issued its quarterly earnings data on Thursday, July 21st. The company reported $0.09 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.03. The business earned $26.30 million during the quarter, compared to the consensus estimate of $24.30 million. Trinity Biotech PLC had a net margin of 15.77% and a return on equity of 3.03%. Equities analysts anticipate that Trinity Biotech PLC will post ($0.19) EPS for the current fiscal year.
TRIB has been the topic of a number of recent analyst reports. Stephens cut shares of Trinity Biotech PLC from an “overweight” rating to an “equal weight” rating in a research report on Wednesday. Zacks Investment Research raised shares of Trinity Biotech PLC from a “sell” rating to a “hold” rating in a research report on Thursday, September 22nd.
About Trinity Biotech PLC
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.
Want to see what other hedge funds are holding TRIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trinity Biotech PLC (NASDAQ:TRIB).
Receive News & Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related companies with MarketBeat.com's FREE daily email newsletter.